Houston energy company exits, 3 recent investments from local fund, and more innovation news

Short stories

From a Houston startup exit to the growth of a Rice University startup, here's the short stories of Houston innovation news you may have missed. Pexels

Houston's innovation ecosystem has been booming with news, and it's likely some might have fallen through the cracks.

For this roundup of short stories within Houston innovation, Texas Halo Fund makes three new investments, a Houston energy company exits, a growing Rice University startup gets grants, and more.

Octopus Energy acquires Houston-founded Evolve Energy

The $5 million deal means a new focus on Texas for the new parent company. Photo via evolvemyenergy.com

London-based renewable energy company Octopus Energy announced that it's acquired Houston-founded Evolve Energy in a $5 million deal, which represents Octopus's $100 million expansion into the United States market.

Octopus, which reached Unicorn status with a $1 billion valuation in April, will start its expansion in Texas, according to a news release, operating under the new name Octopus Energy US. Evolve Energy, which was founded in 2018 by Michael Lee, is a Texas-based Capital Factory portfolio company and finished first place in the 2019 EarthX startup competition. The company also has a Silicon Valley office, in addition to its local operation in Houston's Galleria area.

"Octopus Energy is inspirational in growing a customer base of over 1 million households in just four years. It has done so while also achieving customer satisfaction scores similar to Netflix and Amazon. It matches our aspiration for innovation and we're thrilled to be part of the Octopus family," says Lee in the release. "The US energy market is rapidly moving towards ultra-low cost renewable energy and is prime for a true digital transformation."

Texas Halo Fund makes three new investments

Texas Money

Here are the three latest investments from Texas Halo Fund. Getty Images

Houston-based Texas Halo Fund has made three recent investments in August and September.

  • Nexus AI, based in Chicago, the workforce management tech company uses artificial intelligence and organizational behavioral science to predict the best teams or individuals for a project on the startup's cloud-based platform.
  • Rellevate is a Connecticut-based digital fintech company that optimizes employer-based digital account and financial services.
  • MFB Fertility, a Colorado company, has created game-changing at-home test stripts for assaying the hormone progesterone branded as Proov.

Rice University program seeking data projects

The Rice D2K Lab wants to help startups and small businesses solve business concerns with data science. Photo courtesy of Rice

Adata-focused lab at Rice University is seeking data challenges for its group of next generation of data scientists to solve. The Rice D2K Lab is looking for sponsors for its Rice D2K Capstone project in Spring 2021. Rice's D2K Capstone program forms interdisciplinary teams of advanced undergraduate and graduate students to solve pressing real-world data science challenges. The program is accepting project proposals for the Spring 2021 semester through Monday, October 19.

Click here to learn more about the program, and click here to get involved.

California startup joins Chevron's Catalyst Program

CTV has a new startup in its Catalyst Program. Photo via Getty Images

Houston-based Chevron Technology Ventures announced that Oakland, California-based Brimstone Energy Inc. has joined CTV's Catalyst Program to continue its development of its decarbonization platform, which focuses on the generation of low-emissions hydrogen, as well as various commodity products, according to a release.

"Brimstone Energy is excited to be supported by Chevron, a multi-national industrial company," says Cody Finke, Ph.D., co-founder and CEO of Brimstone Energy, in the release. "It is good to see Chevron continue to back companies with decarbonization in their mission."

Rice University-born startup racks up $12.5 million in grants

OpenStax is growing its access to free online textbooks. Image via openstax.org

Rice University's OpenStax is able to greatly expand its library of free online textbooks thanks to new grants totaling $12.5 million. The funds derive from Bill & Melinda Gates Foundation, the William and Flora Hewlett Foundation, the Charles Koch Foundation and the Stand Together community, according to a press release from Rice.

The new funds will more than double OpenStax's files from 42 books to 90. Already, the platform has saved 14 million students around the world more than $1 billion.

"Nine years ago, we dreamed about solving the textbook affordability and access crisis for students," says Richard Baraniuk, the Victor E. Cameron Professor of Electrical and Computer Engineering at Rice and founder and director of OpenStax, in the release. "Now, with this tremendous investment in open education, we will be able to not only accelerate educational access for tens of millions of students but also drive innovation in high-quality digital learning, which has become commonplace due to COVID-19."

OpenStax is planning to raise $30 million for continued library expansion as it aims to lower the barrier to higher education.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Houston digital health platform Koda lands strategic investment

money moves

Houston-based advance care planning platform Koda Health has added another investor to the lineup.

The company secured a strategic investment for an undisclosed amount from UPMC Enterprises, the commercialization arm of the University of Pittsburgh Medical Center. The funding is part of Koda's oversubscribed series A funding round that closed in October, according to a release.

"UPMC Enterprises’ investment is a meaningful signal, not just to Koda, but to the broader market," Dr. Desh Mohan, chief medical officer and co-founder of Koda Health, said in the news release. "It validates that health systems are ready to invest in infrastructure that makes advance care planning work the way it should: proactively, at scale, and with the human support that these conversations require. Having UPMC Enterprises as a strategic investor puts us in a unique position to prove what's possible."

Koda has raised $14 million to date, according to a representative from the company. Its series A round was led by Evidenced, with participation from Mudita Venture Partners, Techstars and the Texas Medical Center last year. At the time, the company said the funding would allow it to scale operations and expand engineering, clinical strategy and customer success. The company described the round as a "pivotal moment," as it had secured investments from influential leaders in the healthcare and venture capital space.

Koda Health, which was born out of the TMC's Biodesign Fellowship in 2020, saw major growth last year, as well, and now supports more than 1 million patients nationwide through partnerships with Cigna Healthcare, Privia Health, Guidehealth, Sentara, UPMC and Memorial Hermann Health System.

The company integrated its end-of-life care planning platform with Dallas-based Guidehealth in April 2025 and with Epic Systems in July 2025. It also won the 2025 Houston Innovation Award in the Health Tech Business category. Read more here.

UH med school gets $2M gift and more top Houston innovation news

Trending Topics

Editor's note: The top Houston innovation news of the month is full of fresh funding, with two Texas medical schools receiving major gifts — one of historic proportions. Below are the five most-read InnovationMap headlines from April 16-30, 2026.

UH med school granted $2M gift to offer student scholarships

A new scholarship endowment aims to support students in the University of Houston’s recently established medical school. The University of Houston’s Tilman J. Fertitta Family College of Medicine received a planned estate gift commitment estimated at $2.1 million to establish the Bob Diehl and Teresa Evans Diehl Scholarship Endowment. The scholarship will assist full-time medical students who demonstrate financial need and meet academic standards. Continue reading.

How Houston innovators played a role in the historic Artemis II splashdown

Research from Rice University played a critical role in the safe return of U.S. astronauts aboard NASA’s Artemis II mission this month. Rice mechanical engineer Tayfun E. Tezduyar and longtime collaborator Kenji Takizawa developed a key computational parachute fluid-structure interaction (FSI) analysis system that proved vital in NASA’s Orion capsule’s descent into the Pacific Ocean. The FSI system, originally developed in 2013 alongside NASA Johnson Space Center, was critical in Orion’s three-parachute design, which slowed the capsule as it returned to Earth, according to Rice. Continue reading.

Baylor scientist lands $2M grant to explore links between viruses and Alzheimer’s

A Baylor College of Medicine scientist will begin exploring the possible link between Alzheimer’s disease and viral infections thanks to a $2 million grant awarded in March. Dr. Ryan S. Dhindsa hypothesizes that Alzheimer’s may have some link to previous viral infections contracted by the patient. To study this intriguing possibility, the American Brain Foundation has gifted him the Cure One, Cure Many award in neuroinflammation. Continue reading.

New UT Austin med center, anchored by MD Anderson, gets historic gift

A donation announced April 21 breaks a major record at the University of Texas at Austin. Michael and Susan Dell are now UT Austin's first supporters to give $1 billion. In response, the university will create the UT Dell Campus for Advanced Research and the UT Dell Medical Center to "advance human health," per a press release. Continue reading.

Houston VC funding surged nearly 50% in Q1 2026, report says

Houston saw a jump in VC funding in Q1 2026, fueled by several major investments in clean energy startups. Image via Getty Images

First-quarter venture capital funding for Houston-area startups climbed nearly 50 percent compared to the same time last year, according to the PitchBook-NVCA Venture Monitor. In Q1 2026, Houston-area startups raised $532.3 million, a 49 percent jump from $320.2 million in Q1 2025, according to the PitchBook-NVCA Venture Monitor. However, the Q1 total fell 23 percent from the $671.05 million raised in Q4 2025. Continue reading.

New 'living pharmacy' biotech company launches out of Rice venture studio

fighting cancer

Rice University’s biotech venture studio RBL LLC has launched a new “living pharmacy” company, Duracyte, designed to make cancer treatment easier on patients.

Backed by an up to $45 million Advanced Research Projects Agency for Health (ARPA-H) award, Duracyte aims to commercialize implantable biohybrid pharmacy devices that are designed to produce therapeutic proteins inside the human body around the clock, replacing the need for regular injections and infusions for some cancer patients.

The company’s main platform is its Hybrid Advanced Molecular Manufacturing Regulator (HAMMR), a rechargeable, implantable device that can sense biological signals, monitor tumor environments and adjust therapeutic output in real time. HAMMR has wireless communication capabilities, which allow patients and clinicians to remotely monitor results through an app every five minutes and make changes to treatment plans without a hosptial visit. Additionally, the device can generate its own oxygen supply, which is key for the therapeutic cells’ survival.

“Biologic medicines such as monoclonal antibodies, cytokines and metabolic regulators already account for a significant share of modern therapeutics, but the way we deliver them today often requires frequent injections or infusions that can be demanding for patients and lead to inconsistent drug levels,” Daniel Anderson, MIT professor and co-founder of Duracyte, said in a news release. “Our vision is to enable a continuous, stable therapy by producing these medicines directly inside the body, which could improve treatment consistency, reduce side effects and ultimately transform how biologic therapies are delivered across many diseases.”

Duracyte’s first clinical trial is slated to begin by the end of 2026 and will focus on recurrent ovarian cancer. The Phase I study will build upon existing work on encapsulated cytokine pharmacy technology, and the company hopes that within a few years this treatment can reach clinical application.

The development of Duracyte is supported by ARPA-H's Targeted Hybrid Oncotherapeutic Regulation (THOR) project, which supports a multidisciplinary research consortium co-led by Omid Veiseh, a professor of bioengineering at Rice. The consortium also includes others at Rice, The University of Texas MD Anderson Cancer Center, Stanford University, Carnegie Mellon University, Northwestern University and the University of Houston, plus industry collaborators like Chicago-based CellTrans.

“What we are building is the culmination of years of progress in cell engineering, biomaterials and implantable device technology,” Veiseh added in the release. “By combining these advances with real-time sensing and adaptive drug delivery, we are working with the support of RBL to create a true ‘living pharmacy’ that can deliver continuous, precisely controlled biologic therapies and fundamentally change how these treatments reach patients.”

RBL launched in 2024 and is based out of Houston’s Texas Medical Center Helix Park. Duracyte is the third company launched by RBL, including Sentinel BioTherapeutics, a clinical-stage immunotherapy company developing localized cytokine therapies for solid tumors, and SteerBio, a regenerative medicine company targeting lymphedema.

“Duracyte exemplifies the kind of breakthrough that Houston’s ecosystem is built to produce,” Paul Wotton, managing partner of RBL LLC and co-founder of Duracyte, added in the release. “With world-class clinical infrastructure, exceptional engineering talent and initiatives like the Texas Biotech Task Force driving alignment across industry, investment and talent, this region is uniquely positioned to move the most ambitious ideas in medicine from concept to patient, faster than anywhere else.”

View All Listings